Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS OTCMKTS:IPHYF NASDAQ:IRWD NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.58+1.6%$4.21$1.34▼$5.15$629.88M0.761.17 million shs683,450 shsIPHYFInnate Pharma$1.65-26.7%$1.65$1.37▼$2.25$188.62M0.2510 shs6,700 shsIRWDIronwood Pharmaceuticals$3.71-4.9%$3.78$0.56▼$5.78$635.93M0.292.62 million shs2.94 million shsRLMDRelmada Therapeutics$7.26+1.3%$7.02$0.52▼$8.00$752.06M0.43924,447 shs555,956 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-0.22%+1.35%+4.76%+36.25%+257.94%IPHYFInnate Pharma0.00%0.00%+50.00%+4.41%+55.17%IRWDIronwood Pharmaceuticals-0.51%+6.27%-0.76%+16.07%+588.68%RLMDRelmada Therapeutics+1.85%+1.99%-0.55%+57.58%+1,021.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$4.58+1.6%$4.21$1.34▼$5.15$629.88M0.761.17 million shs683,450 shsIPHYFInnate Pharma$1.65-26.7%$1.65$1.37▼$2.25$188.62M0.2510 shs6,700 shsIRWDIronwood Pharmaceuticals$3.71-4.9%$3.78$0.56▼$5.78$635.93M0.292.62 million shs2.94 million shsRLMDRelmada Therapeutics$7.26+1.3%$7.02$0.52▼$8.00$752.06M0.43924,447 shs555,956 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-0.22%+1.35%+4.76%+36.25%+257.94%IPHYFInnate Pharma0.00%0.00%+50.00%+4.41%+55.17%IRWDIronwood Pharmaceuticals-0.51%+6.27%-0.76%+16.07%+588.68%RLMDRelmada Therapeutics+1.85%+1.99%-0.55%+57.58%+1,021.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.00Buy$11.29146.41% UpsideIPHYFInnate Pharma 0.00N/AN/AN/AIRWDIronwood Pharmaceuticals 2.43Hold$6.2368.01% UpsideRLMDRelmada Therapeutics 2.71Moderate Buy$12.0065.29% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, RLMD, IRWD, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ACRSAclaris Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $11.005/5/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/4/2026ACRSAclaris Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $10.004/27/2026IRWDIronwood Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)4/16/2026ACRSAclaris Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.004/16/2026ACRSAclaris Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.003/31/2026ACRSAclaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.003/27/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026RLMDRelmada Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.003/20/2026RLMDRelmada Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $19.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M81.69N/AN/A$1.03 per share4.45IPHYFInnate Pharma$10.19M13.57N/AN/A($0.29) per share-5.69IRWDIronwood Pharmaceuticals$296.15M2.04$0.24 per share15.15($1.33) per share-2.79RLMDRelmada TherapeuticsN/AN/AN/AN/A$2.09 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)IPHYFInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/AIRWDIronwood Pharmaceuticals$24.02M$0.606.18N/AN/A28.26%-39.65%26.54%8/6/2026 (Estimated)RLMDRelmada Therapeutics-$57.38M-$1.09N/AN/AN/AN/A-71.22%-64.46%8/6/2026 (Estimated)Latest IPHYF, RLMD, IRWD, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026RLMDRelmada Therapeutics-$0.18-$0.22-$0.04-$0.22N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million5/7/2026Q1 2026IRWDIronwood Pharmaceuticals$0.2467$0.24-$0.0067$0.24$92.11 million$106.51 million3/19/2026Q4 2025RLMDRelmada Therapeutics-$0.14-$0.27-$0.13-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03IPHYFInnate PharmaN/A1.271.27IRWDIronwood PharmaceuticalsN/A1.411.41RLMDRelmada TherapeuticsN/A18.2518.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%IPHYFInnate PharmaN/AIRWDIronwood PharmaceuticalsN/ARLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%IPHYFInnate Pharma31.89%IRWDIronwood Pharmaceuticals9.30%RLMDRelmada Therapeutics14.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million131.84 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableIRWDIronwood Pharmaceuticals220163.06 million147.89 millionOptionableRLMDRelmada Therapeutics10104.89 million89.68 millionOptionableIPHYF, RLMD, IRWD, and ACRS HeadlinesRecent News About These CompaniesRelmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ...May 13, 2026 | finance.yahoo.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comRelmada Therapeutics Q1 Earnings Call HighlightsMay 12, 2026 | marketbeat.comRelmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 9, 2026 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Time to Buy?May 6, 2026 | marketbeat.comRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026May 6, 2026 | globenewswire.comRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026May 5, 2026 | globenewswire.comRelmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comMizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)April 16, 2026 | theglobeandmail.comDoes Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?April 13, 2026 | zacks.com5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthApril 2, 2026 | zacks.comRelmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And SeeMarch 30, 2026 | seekingalpha.comWall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should KnowMarch 26, 2026 | zacks.comHere’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) StockMarch 25, 2026 | msn.comRelmada wins bullish view at Piper Sandler on cancer therapyMarch 24, 2026 | seekingalpha.comPiper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendationMarch 24, 2026 | msn.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 earnings call transcriptMarch 20, 2026 | msn.comRelmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ...March 20, 2026 | sg.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call TranscriptMarch 19, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHYF, RLMD, IRWD, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$4.58 +0.07 (+1.55%) Closing price 04:00 PM EasternExtended Trading$4.53 -0.05 (-1.18%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Innate Pharma OTCMKTS:IPHYF$1.65 -0.60 (-26.67%) As of 12:16 PM EasternInnate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Ironwood Pharmaceuticals NASDAQ:IRWD$3.71 -0.19 (-4.87%) Closing price 04:00 PM EasternExtended Trading$3.72 +0.02 (+0.40%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Relmada Therapeutics NASDAQ:RLMD$7.26 +0.09 (+1.26%) Closing price 04:00 PM EasternExtended Trading$7.11 -0.15 (-2.07%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
